Trial Profile
A Study of DHP107, a Novel Oral Paclitaxel Formulation, to Determine Maximum Tolerated Dose and Recommended Dose for Phase II Trial in Patients With Advanced Solid Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 15 Feb 2017
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Gastric cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Daehwa Pharmaceutical
- 05 Dec 2015 New trial record